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INTRODUCTION
The Third Report of the National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) proposed
the importance of the metabolic syndrome in assessing and
managing cardiovascular diseases (1). People with the metabol-
ic syndrome are at an increased risk for morbidity as well as
mortality from cardiovascular disease (2, 3). Abdominal obe-
sity, particularly visceral obesity promotes the insulin resistance
(4-6), and also causes the clustering of cardiovascular risk fac-
tors at a given level of body mass index (BMI) (7, 8). A high
waist circumference, a good predictor of cardiovascular disease
(9), is one of important diagnostic standpoints of the metabolic
syndrome. A recent prospective study has shown that obesity
appears to be the central component of the metabolic syndrome
(10), and thus, identification of these high-risk individuals
would be crucial in order to provide appropriate therapy with
the currently available disease-modifying treatments along
with the recommendation of weight reduction as first-line
treatment (1).
Korea, like other Asian countries, has experienced rapid
socioeconomic growth with prominent lifestyle transforma-
tion over the past several decades. The cardiovascular dis-
eases is being witnessed as one of the most common causes of
death in Korea (11). Asians tend to show a high prevalence of
cardiovascular risk factors at even lower BMI compared to
Caucasians, presumably due to a greater central obesity (8). The
prevalence of metabolic syndrome has been reported to be more
than 20% among Koreans despite a lower prevalence of
obesity (12). However, the BMI increment was identified as
one of independent modifiable risk factors of the metabolic
syndrome among Koreans (12).
The modification of associated factors is known to be essen-
tial to prevent and to manage the metabolic syndrome. How-
ever, little information is available regarding the effect of
weight reduction or change of fat distribution on the metabolic
components in obese patients among Koreans. The aims of
this study were to examine the change of anthropometric in-
dices, fat distribution, and metabolic components with mod-
est weight reduction (5-10%), to compare the efficacy of weight
reduction in patients with or without the metabolic syndrome,
and to investigate the predictable variables for improvement
of the metabolic components and insulin resistance during
weight reduction in Korean obese patients.
MATERIALS AND METHODS
Recruitment of subjects
Our study included 78 obese patients (BMI ≥25 kg/m2)
aged 15-60 yr (19 males and 59 females) who visited the Obe-
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Patients
The Third Report of the National Cholesterol Education Program Adult Treatment
Panel III emphasized the importance of management of the metabolic syndrome.
However, little information is available about the effect of weight reduction on the
metabolic syndrome in obese patients among Koreans. A longitudinal clinical inter-
vention study from the 12-week of weight reduction program, including life style modi-
fication and adjuvant appetite suppressants, in 78 obese persons was performed.
Anthropometry and metabolic risk factors were measured before and after weight
reduction. Visceral (VAT), subcutaneous (SAT), and total adipose tissue (TAT) on
abdomen were determined by CT scan. Moderate decrease in weight (9.3%) induced
significant reduction of waist circumference, systolic and diastolic blood pressure, and
triglyceride. Weight reduction also resulted in significant decrease in total cholesterol,
LDL-C, uric acid, fasting insulin, and HOMA score. The subjects with metabolic syn-
drome showed more improvements of metabolic components than those without
metabolic syndrome through weight reduction. The reductions of visceral-subcuta-
neous fat ratio (VSR) and waist circumference were observed as for the predictable
variables related to the improvement of metabolic component and insulin resistance
in Korean obese patients.
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sity Clinic in Asan Medical Center. This study was approved
by the Institutional Review of Board of Asan Medical Center.
The subjects excluded from this study were pregnant or lac-
tating women, and those with secondary causes of obesity and
evidence of severe hepatic or renal diseases. Also, the subjects
who were taking medications that might have had affect on
the metabolic components of metabolic syndrome (e.g., anti-
hypertensive drug, oral hypoglycemic agents, insulin, hypolipi-
demic agents, and lipase inhibitors) were excluded. All indi-
viduals were subjected to a medical evaluation by physicians
who were responsible for taking full medical history and phys-
ical examination.
Anthropometric measurements
Anthropometric measurements were taken with the sub-
jects in light clothing and without shoes. Height and weight
were measured by an automatic height-weight scale, to the
nearest 0.1 cm and 0.1 kg. Body mass index (BMI) was cal-
culated by dividing weight (kg) by square of height (m2). Per-
cent body fat and total body fat were then measured by bioim-
pedance analysis (Inbody 3.0, Biospace, Seoul, Korea) (13). The
waist circumference was measured at the midpoint between
the lower border of the rib cage and the iliac crest, and the
hip circumference at the widest part of the hip region. Only
one well trained technician checked the anthropometric mea-
surements throughout the whole process of this study to redu-
ce the interpersonal variations. The waist-to-hip ratio (WHR)
was calculated by dividing the waist circumference by the
hip circumference.
Computed tomography
Cross-sectional abdominal visceral and subcutaneous adi-
pose tissue areas were measured by computed tomography
(CT) on a Siemens Somaton Scanner (Erlangen, Germany) using
an established protocol (14, 15). A cross-sectional scan at 10-
mm thickness centered at the L4-L5 vertebral disc space with
the subject in the supine position was obtained using a radio-
graph of the skeleton as a reference to establish the position
of the scans to the nearest millimeter. Subcutaneous and vis-
ceral adipose tissue (SAT and VAT) boundaries were defined
using a manual cursor by delineating these areas with a graph
pen, and the adipose tissue areas were calculated by comput-
ing the adipose tissue surfaces with an attenuation range of
-190 to -30 Hounsfield units. The abdominal VAT area was
measured by drawing a line within the muscle wall surround-
ing the abdominal cavity. The SAT area was calculated by sub-
tracting the VAT area from the total adipose tissue (TAT) area
and the VAT to SAT ratio (VSR) was then calculated.
Metabolic variables
The metabolic components of the metabolic syndrome (e.g.,
blood pressure, fasting blood glucose, triglyceride, and HDL-
cholesterol) as well as other metabolic variables (total choles-
terol, LDL-cholesterol, uric acid, fasting insulin and HOMA
score) were measured in the study subjects before and after
weight reduction.
Blood pressure was measured with a mercury sphygmoma-
nometer after 10 min rest in the sitting position. All study
subjects were refrained from smoking or ingesting caffeine for
30 min preceding the measurements. Cuff size was selected
according to arm circumference of the participants. The first
appearance of sound (phase 1 Korotkoff sound) was used to
define systolic blood pressure and the disappearance of sound
(phase 5 Korotkoff sound) was used to define diastolic blood
pressure (16). Two readings for each of systolic and diastolic
blood pressure were recorded and the average of each measure-
ment was used. If the first two measurements differed by more
than 5 mmHg, additional readings were obtained.
Blood samples were obtained in the morning after a 12 hr
overnight fast from an antecubital vein into vacutainer tubes
containing EDTA and subsequently analyzed at a central, cer-
tified laboratory. Plasma glucose was measured by a glucose
oxidase method, and total cholesterol and triglyceride levels
by enzymatic procedures using an autoanalyzer (Hitachi-747,
Tokyo, Japan). The HDL-cholesterol fraction was measured
by enzymatic method after precipitation of apo-B containing
lipoproteins with MnCl2. LDL cholesterol was calculated by
Friedewald equation if triglyceride was below 400 mg/dL (17).
The uric acid concentrations were measured by uricase method
using autoanalyzer. Fasting insulin was measured by radioim-
munoassay (Dianabott, Tokyo, Japan). The estimate of insulin
resistance by HOMA score was calculated with the formula:
fasting serum insulin ( U/mL)×fasting plasma glucose (mmol/
L)/22.5 (18).
Participants having 3 or more of the following criteria were
defined as having the metabolic syndrome; blood pressure:
≥130/≥85 mmHg; fasting glucose: ≥110 mg/dL; hyper-
triglyceridemia: ≥150 mg/dL; and low HDL-cholesterol:
<40 mg/dL in men and <50 mg/dL in women, and abdom-
inal obesity: waist circumference >102 cm in men and >88
cm in women as detailed in the NCEP ATP III report (1).
Weight reduction program
The weight reduction program consisted of life style mod-
ification and adjuvant pharmacotherapy using appetite sup-
pressants. Unrestricted routine dietary intake of subjects was
assessed by 24-hr dietary recall. For this, experienced, well-
trained interviewers instructed respondents to recall and de-
scribe all foods and beverages they had consumed over the past
24 hr. Each subject’ s record was coded and standardized ref-
erence tables were used to convert household portions to gram
weights. The nutrient analysis of the records was quantified
using a computer aided nutritional analysis program (CAN,
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gy deficits were based on the estimated energy requirements
calculated from a basal metabolic rate multiplied by a physical
activity level (20). The basal metabolic rate was assessed by
the Benedict-Harris equation. A well-trained dietitian instruct-
ed the daily energy prescriptions for weight reduction.
Diet regimen used in this study was a balanced diet no less
than 1,000 kcal/day composed of carbohydrate 60% of total
energy intake with the fat level below 30% of calories. Restric-
tion of alcohol consumption either by reducing the frequency
or the amount of alcohol beverage was strongly recommended
to all subjects. However, the subjects were free to select the
type of the foods and beverages, and to keep the food diaries
recorded three times per week during the 12-week study peri-
od. The dietitians interviewed the subjects at regular basis, once
a month, and reevaluated their total intake of energy and nutri-
ents from food diaries. They monitored to ensure each patient
to follow diet habit according to recommended proper nutri-
tion for such subject.
The physical activity level of all subjects was assessed using
a questionnaires categorized into one of the following groups
of physical activity level: inactive, mildly active daily life (no
outside exercise), moderately active daily life (formal exercise
less than 3 times/week), and severely active daily life (formal
exercise more than 3 times/week). Most of the subjects were
categorized in inactive or mildly active. Based on initial phys-
ical activity level, the subjects were also encouraged to increased
levels of daily exercise and to reduce the amount of time spent
in a sedentary life style.
The initial duration of exercise was about 30 min, but was
progressed to a maximum of 60 min according to individual
capabilities. The exercise intensity was increased from 50%
to 85% of the maximum heart rate. The mode of exercise was
determined by the subjects and varied from walking, cycling,
swimming, stationary cycling, or walking on a motorized tread-
mill under unrestricted living condition. Throughout the study,
the interviewer monitored the compliance for exercise using
a diary and reevaluated physical activity level.
The subjects were prescribed with adjuvant appetite sup-
pressant for weight reduction, because they usually failed wei-
ght control with life style modification alone. Selective sero-
tonin reuptake inhibitor (fluoxetine 40 mg) was prescribed
during the 12-week weight reduction program. The subjects
finished the 12-week weight reduction program and follow-
up reassessment were taken including anthropometric mea-
surements, abdominal fat CT scan, and metabolic variables.
Statistical analyses
The results are presented as mean±SD. The changes of
anthropometric measurements, abdominal fat distribution,
and metabolic variables before and after the weight reduction
program in the subjects were tested by the paired t-test. The
changes of all variables between the patients with or without
the metabolic syndrome were compared by the Student t-test.
The stepwise multiple regression analysis was used to inves-
tigate the predictable variables for the improvement of metabol-
ic variables. All analyses were two-tailed and a p-value <0.05
was considered statistically significant. The statistical analyses
were performed using SAS 6.12 for Windows (SAS institute
Inc. Cary, NC, U.S.A.).
RESULTS
Effect of weight reduction on anthropometric variables
and abdominal fat distribution
Table 1 shows the changes and the percent changes of the
anthropometric variables and abdominal fat distribution after
12 weeks of weight reduction program in the study subjects.
When compared to the basal state, body weight, BMI, body
fat, fat mass, and fat free mass were significantly reduced (p<
0.05). With regards to abdominal fat distribution, waist cir-
cumference, hip circumference, WHR, TAT, SAT, VAT, and
VSR were significantly reduced (p<0.05) as well.
Effect of weight reduction on metabolic variables
The absolute mean and percent reductions in the variables
of the metabolic syndrome or insulin resistance from baseline
to 12 week of weight reduction are summarized in Table 2.
Systolic and diastolic blood pressure, triglyceride, total choles-
terol, LDL-cholesterol, uric acid, fasting insulin, and HOMA
scores were significantly reduced (p<0.05). However, the fast-
ing blood glucose and HDL-cholesterol were not significantly
changed after 12 weeks of intervention compared to the base-
line measurements of the study subjects.
Values are expressed as mean (SD). *p<0.05 by paired t-test.
BMI, body mass index; WHR, waist hip ratio; TAT, total adipose tissue;
SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; VSR,
visceral subcutaneous fat ratio.
0 week 12 week Change % Change
Weight (kg) 82.0 (18.3) 73.9 (14.7) -8.1 (6.1)* -9.3 (5.4)*
BMI (kg/m
2) 31.2 (4.4) 28.1 (3.4) -3.0 (2.1)* -9.3 (5.4)*
Body fat (%) 33.6 (5.1) 30.5 (5.5) -3.3 (4.1)* -9.2 (12.0)*
Fat mass (kg) 27.7 (7.6) 22.9 (6.0) -5.5 (4.7)* -18.0 (13.0)*
Fat free mass 54.7 (12.9) 52.4 (11.8) -3.3 (4.0)* -5.4 (6.8)*
(kg)
Waist (cm) 97.1 (11.6) 90.6 (9.8) -6.6 (6.2)* -6.5 (5.9)*
Hip (cm) 106.3 (8.3) 101.4 (7.0) -4.8 (4.6)* -4.4 (4.0)*
WHR 0.91 (0.07) 0.89 (0.06) -0.02 (0.05)* -2.1 (5.4)*
TAT (cm
2) 424.0 (115.2) 340.2 (100.6) -82.1 (85.9)* -18.0 (16.6)*
SAT (cm
2) 299.4 (105.7) 245.4 (83.5) -52.8 (73.5)* -14.3 (22.2)*
VAT (cm
2) 124.7 (53.9) 94.8 (47.8) -29.3 (34.5)* -22.9 (19.5)*
VSR 0.47 (0.31) 0.41 (0.23) -0.06 (0.23)* -6.4 (25.4)*
Table 1. Changes of anthropometric variables and abdominal fat
distribution after 12 weeks weight reduction program in 78 obese
subjectsEffect of Weight Reduction on Metabolic Syndrome 205
Comparison the effect of weight reduction on anthropo-
metric variables and fat distribution between the subjects
with or without metabolic syndrome
Table 3 shows the baseline and changes of anthropometric
variables and abdominal fat distribution after 12 weeks of wei-
ght reduction program in the subjects with or without meta-
bolic syndrome. The age, baseline anthropometric variables,
and abdominal fat distribution were not significantly differ-
ent between two groups. Also, the changes of weight, BMI,
waist circumference, TAT, SAT, VAT, and VSR were not sig-
nificantly different between these groups. However, individ-
Values are expressed as means (SD). *p<0.05 paired t-test.
SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fast-
ing blood glucose; TG, triglyceride; HDL-C, HDL-cholesterol; TC, total
cholesterol; LDL-C, LDL-cholesterol; HOMA, homeostasis model assess-
ment.
0 week 12 week Change % Change
SBP (mmHg) 130.7 (14.3) 121.0 (13.1) -9.8 (15.9)* -6.7 (12.3)*
DBP (mmHg) 77.0 (11.1) 72.6 (10.8) -4.4 (12.1)* -4.4 (16.0)*
FBG (mg/dL) 98.8 (22.1) 95.8 (16.2) -3.8 (17.1) -2.0 (13.4)
TG (mg/dL) 139.8 (105.4) 126.6 (74.3) -14.4 (65.1)* -2.0 (40.3)
HDL-C (mg/dL) 48.8 (12.2) 47.5 (11.2) -0.8 (7.0) -0.8 (14.4)
TC (mg/dL) 205.8 (38.2) 193.0 (37.6) -13.4 (28.9)* -5.6 (13.9)*
LDL-C (mg/dL) 131.0 (33.7) 122.2 (29.9) -13.8 (27.2)* -8.0 (20.3)*
Uric acid (mg/dL) 5.5 (1.8) 5.1 (1.6) -0.6 (0.8)* -9.1 (14.0)*
Insulin ( IU /mL) 12.0 (8.6) 8.5 (6.0) -3.1 (4.8)* -20.0 (40.5)*
HOMA score 2.68 (1.89) 1.87 (1.43) -0.81 (1.16)* -21.6 (43.4)*
Table 2. Changes of metabolic variables after 12 weeks weight
reduction program in 78 obese subjects
Values are expressed as means (SD). *p<0.05 by Student t-test.
BMI, body mass index; TAT, total adipose tissue; SAT, subcutaneous
adipose tissue; VAT, visceral adipose tissue; VSR, visceral subcutaneous
fat ratio.
With metabolic 
syndrome (n=33)
Without metabolic
syndrome (n=45)
Sex (M/F)                                   8/25                                     11/34
Baseline anthropometric variables and fat distribution
Age (yr) 38.3 (13.4) 36.5 (14.2)
Weight (kg) 84.2 (19.1) 80.4 (17.7)
BMI (kg/m
2) 31.8 (4.5) 30.7 (4.3)
Body fat (%) 33.5 (5.1) 33.7 (5.2)
Waist (cm) 99.9 (10.7) 95.0 (11.8)
TAT (cm
2) 439.9 (96.5) 412.2 (127.1)
SAT (cm
2) 309.3 (101.4) 292.0 (109.4)
VAT (cm
2) 130.6 (49.9) 120.3 (56.9)
VSR 0.50 (0.37) 0.45 (0.26)
Change of anthropometric variables and fat distribution
△Weight (kg) -8.9 (7.0) -7.5 (5.4)
△BMI (kg/m
2) -3.3 (2.3) -2.8 (1.8)
△Body fat (%)* -4.5 (3.8) -2.3 (4.1)
△Waist (cm) -7.2 (7.1) -6.0 (5.5)
△TAT (cm
2) -92.0 (92.9) -74.7 (80.7)
△SAT (cm
2) -59.8 (85.1) -47.6 (64.0)
△VAT (cm
2) -32.2 (39.0) -27.1 (30.9)
△VSR -0.09 (0.31) -0.04 (0.13)
Table 3. Comparison of the change of anthropometric variables
and fat distribution in the subjects with or without metabolic syn-
drome after 12 weeks weight reduction program
Values are expressed as means (SD). *p<0.05 by Student t-test.
SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fast-
ing blood glucose; TG, triglyceride; HDL-C, HDL-cholesterol; TC, total
cholesterol; LDL-C, LDL-cholesterol; HOMA, homeostasis model assess-
ment.
With metabolic 
syndrome (n=33)
Without metabolic
syndrome (n=45)
Sex (M/F)                                     8/25                                  11/34
Baseline metabolic variables
SBP (mmHg)* 138.4 (11.7) 125.1 (13.4)
DBP (mmHg)* 81.3 (11.6) 73.8 (9.6)
FBG (mg/dL)* 106.6 (29.6) 92.3 (9.2)
TG (mg/dL)* 185.7 (140.0) 102.4 (36.7)
HDL-C (mg/dL)* 42.6 (9.1) 53.7 (12.3)
TC (mg/dL) 208.3 (40.3) 203.7 (36.8)
LDL-C (mg/dL) 133.5 (36.2) 129.3 (32.1)
Uric acid (mg/dL) 5.9 (1.8) 5.2 (1.7)
Insulin ( IU /mL) 13.3 (8.8) 10.7 (8.3)
HOMA score 3.14 (1.82) 2.24 (1.87)
Change of metabolic variables
△SBP (mmHg)* -13.6 (15.5) -6.9 (15.7)
△DBP (mmHg)* -7.6 (12.6) -1.9 (11.2)
△FBG (mg/dL)* -9.6 (19.5) +1.2 (13.0)
△TG (mg/dL)* -29.7 (81.3) +0.03 (41.7)
△HDL-C (mg/dL) -0.3 (6.6) -1.3 (7.4)
△TC (mg/dL) -18.9 (33.7) -8.8 (23.6)
△LDL-C (mg/dL) -16.6 (33.5) -11.5 (21.1)
△Uric acid (mg/dL) -0.61 (0.93) -0.62 (0.70)
△Insulin ( IU /mL)* -4.2 (4.6) -1.7 (4.7)
△HOMA score* -1.19 (1.12) -0.35 (1.05)
Table 4. Comparison of the change of metabolic variables in the
subjects with or without metabolic syndrome after 12 weeks wei-
ght reduction program
SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fast-
ing blood glucose; TG, triglyceride; HDL-C, HDL-cholesterol; HOMA,
homeostasis model assessment; VSR, visceral subcutaneous fat ratio;
VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.
Dependent variable Independent
variable
R
2 (%) p-value
△SBP (mmHg) None
△DBP (mmHg) None
△FBG (mg/dL) △VSR 27.5 35.2 0.0001
△TG (mg/dL) △VSR 33.9 86.1 <0.0001
△VAT 4.7 0.36 0.0677
△HDL-C (mg/dL) None
△Insulin ( IU /mL) △Waist 14.4 0.30 0.0224
△HOMA score △Waist 18.7 0.11 0.0095
△SAT 7.3 -0.01 0.0854
Table 5. Relationship between the change of metabolic com-
ponents of metabolic syndrome or insulin resistance and the
change of anthropometic measurements or fat distribution after
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uals with the metabolic syndrome significantly lost more body
fat than those without the metabolic syndrome (p<0.05).
Comparison the effect of weight reduction on metabolic
variables between the subjects with or without metabolic
syndrome
Table 4 shows baseline metabolic variables and changes of
metabolic variables after 12 weeks of weight reduction pro-
gram in the subjects with or without metabolic syndrome.
There were significant differences in systolic and diastolic blood
pressure, fasting blood glucose, triglyceride, and HDL-choles-
terol between individuals with metabolic syndrome and those
without the metabolic syndrome (p<0.05). Individuals with
the metabolic syndrome showed significantly greater reduc-
tions in systolic and diastolic blood pressure, fasting blood
glucose, triglyceride, fasting insulin and HOMA score com-
pared to those without the metabolic syndrome (p<0.05).
Predictable variables for the change of metabolic compo-
nents of metabolic syndrome or insulin resistance 
Table 5 indicates the results of stepwise multiple regression
analysis for the independent relationship between the change
of metabolic components of metabolic syndrome or insulin
resistance and the change of anthropometric measurements or
fat distribution. The change of VSR predicted significantly
the change of fasting blood glucose and triglyceride with 27.5%
and 33.9% of R2, respectively (p<0.05). The change of fast-
ing insulin and HOMA score were independently related with
the change of waist circumference (p<0.05).
Change of the frequency of each or clustering of metabolic
component of metabolic syndrome
In overall, there was a reduction in the number of individ-
uals who met the criteria for the metabolic syndrome after
weight reduction compared with baseline. The frequency of
each metabolic component of metabolic syndrome from base-
line to 12 week of weight reduction were changed as follow-
ing; abdominal obesity (70.5% to 52.6%), high blood pres-
sure (55.1% to 30.8%), high fasting blood glucose (14.1%
to 10.3%), hypertriglyceridemia (26.9% to 21.8%), and low
HDL-cholesterol (56.4% to 60.3%). The frequency of clus-
tering of metabolic component of metabolic syndrome from
baseline after 12 weeks of weight reduction were changed as
following; one or more (89.5% to 82.1%), two or more (79.5%
to 65.4%), three or more (42.3% to 25.6%), and four or more
(11.5% to 2.6%). The changes of frequency of the metabolic
variables were depicted in Fig. 1 and 2.
DISCUSSION
The NCEP ATP III has identified the metabolic syndrome
as a secondary target of therapy, beyond lowering cholesterol
(1). A recent prospective principal component analysis showed
that BMI was the central feature of the metabolic syndrome
over time (10). The BMI increment was also identified as an
independent modifiable risk factor of the metabolic syndrome
in Koreans despite a lower prevalence of obesity (12). Weight
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Fig. 1. Frequency of each components of the metabolic syndrome
between 0 and 12 week after weight reduction program in the study
subjects. WC, waist circumference; HDL-C, HDL-cholesterol; BP,
blood pressure; TG, triglyceride; FBG, fasting blood glucose.
The frequency of each component of metabolic syndrome from
baseline to 12 week of weight reduction were changed as follow-
ing; abdominal obesity (70.5% to 52.6%), low HDL-cholesterol
(56.4% to 60.3%), high blood pressure (55.1% to 30.8%), hyper-
triglyceridemia (26.9% to 21.8%), and high fasting blood glucose
(14.1% to 10.3%).
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Fig. 2. Frequency of clustering of metabolic component of the me-
tabolic syndrome between 0 and 12 week after weight reduction
program in the study subjects. RF, risk factor.
The frequency of clustering of metabolic component of metabol-
ic syndrome from baseline to 12 week of weight reduction were
changed as following; one or more (89.5% to 82.1%), two or more
(79.5% to 65.4%), three or more (42.3% to 25.6%), and four or more
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reduction may play an essential role in preventing and man-
aging such metabolic syndrome. The recent Finnish Diabetes
Prevention Trial (21) and the Diabetes Prevention Program
(DPP) (22) have demonstrated the efficacy of even modest
weight reduction, produced by modest changes in diet and
physical activity, in preventing diabetes in overweight patients
with impaired glucose tolerance.
Our study results indicate that average 8.1 kg weight reduc-
tion induced 18.0% loss of total body fat mass and 5.4% loss
of fat free mass with 6.6 cm reduction in waist circumference
accompanied by 22.9% of visceral fat loss and 14.3% of sub-
cutaneous fat loss. These finding are comparable with other
reports on weight reduction from different countries (23, 24).
Above findings also indicate that visceral fat responds more
promptly to weight reduction than subcutaneous fat. That is
agreeable with other study results that visceral adipose tissue
was more metabolically active and lipolytic than subcutaneous
adipose tissue (25). Moreover, this study shows that moderate
weight reduction (9.3% of initial body weight) would result
in substantial reductions of metabolic risk factors related to
the metabolic syndrome or insulin resistance. Among vari-
ous metabolic variables studied, fasting insulin and HOMA
score that serve as surrogate markers of insulin resistance, re-
sponded more sensitively to weight reduction than any other
metabolic variables.
It is observed in this study that obese patients with metabol-
ic syndrome lose, at similar degrees, total heaviness (weight
and BMI), and fat distribution (TAT, SAT, VAT, VSR, and
waist circumference) as individuals without metabolic syn-
drome. Thus, it indicates that the prognosis of obese patients
even with metabolic syndrome might not be that poor if these
patients try hard to lose weight. If we apply the criteria for
abdominal obesity as waist circumference above 90 cm in men
and 80 cm in women suggested by Asia-Pacific guidelines
(26), same results were obtained.
While the differences of the changes of metabolic variables
between the participants with or without metabolic syndrome
were compared, the systolic and diastolic blood pressure, fast-
ing glucose, triglyceride, fasting insulin, and HOMA score
were significantly reduced more in the individuals with me-
tabolic syndrome compared to those without it. This result
indicates that there are greater metabolic benefits among the
individuals with metabolic syndrome despite similar degree
of weight reduction. This finding is in concordant with pre-
vious studies wherein the effectiveness of weight reduction
as a therapeutic strategy was particularly useful for individ-
uals with abnormal levels of metabolic risk factors (27, 28).
Other studies have also shown that weight reduction improves
insulin resistance (29, 30) and individuals with insulin resis-
tance can lose weight as effectively as insulin sensitive indi-
viduals (31).
With regards to the predictive variables for the improvement
of metabolic components, the reductions of visceral-subcuta-
neous fat ratio (VSR) was found to be the independent pre-
dictable variable for the improvement of fasting blood glucose
and triglyceride, and the change of waist circumference was
significantly related with the improvement of fasting insulin
and HOMA score. This would mean that the reduction of
abdominal fat distribution plays an important role in improv-
ing metabolic component and insulin resistance independent
of the change of weight or BMI.
After weight reduction in obese patients, the frequency of
each or clustering of metabolic risk factors was significantly
decreased. Compared to start of intervention of this program,
the frequency of metabolic syndrome was decreased from
42.3% to 25.6% (40% reduction) after weight reduction.
Such findings bring to attention that, despite the persistence
of obesity even after weight reduction, even modest weight
reduction can result in clinically and statistically significant
improvement of metabolic syndrome. If we apply the crite-
ria of metabolic syndrome set by WHO (32), the frequency
of metabolic syndrome would be lower than that would have
been assessed by NCEP ATP III.
The limitations of this study are not generalizing to the nor-
mal weight population and not having been able to observe
the effect of weight reduction on metabolic syndrome in par-
ticipants according to the compliance of weight reduction pro-
gram.
In conclusion, a moderate weight reduction was associated
with substantial reduction in metabolic risk factors of metabol-
ic syndrome or insulin resistance in obese patients that appeared
to be partially mediated by the corresponding reductions in
abdominal fat distribution. The benefit of weight reduction
was found to be greater among individuals with the metabol-
ic syndrome than in those without the metabolic syndrome.
Future clinical research studies are needed to develop ideal
methods to maintain these benefits of weight reduction in
patients with the metabolic syndrome.
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